Triple-negative breast cancer (TNBC) accounts for ∼15% of all breast cancer cases and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) (Oakman et al., 2010). This evidence concerns the gene PGR and triple-negative breast carcinoma.